Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
暂无分享,去创建一个
E. Raymond | H. Lenz | S. Faivre | C. Lombard-Bohas | J. Posey | N. Meropol | A. Lamarca | J. Valle | J. Raoul | I. Borbath | M. Kulke | J. Barriuso